Rani Therapeutics Holdings Inc RANI.OQ RANI.O is expected to show a rise in quarterly revenue when it reports results on March 26 for the period ending December 31 2025
The San Jose California-based company is expected to report a 386.4% increase in revenue to $5 million from $1.03 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Rani Therapeutics Holdings Inc is for a loss of 7 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $8.00, about 601.8% above its last closing price of $1.14
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.12 | -0.12 | -0.12 | Met | 2.7 |
Jun. 30 2025 | -0.19 | -0.19 | -0.18 | Beat | 7.7 |
Mar. 31 2025 | -0.22 | -0.20 | -0.22 | Missed | -8.2 |
Dec. 31 2024 | -0.25 | -0.27 | Missed | -9.5 | |
Sep. 30 2024 | -0.20 | -0.26 | -0.24 | Beat | 6.7 |
Jun. 30 2024 | -0.33 | -0.31 | -0.26 | Beat | 16.8 |
Mar. 31 2024 | -0.21 | -0.21 | -0.29 | Missed | -38.1 |
Dec. 31 2023 | -0.32 | -0.31 | -0.27 | Beat | 13.4 |
This summary was machine generated March 24 at 20:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)